45 results about "Apolipoprotein B" patented technology

The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided.

A method of reducing the serum level in a mammal of any one more cholesterol, low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, apolipoprotein B, and triglycerides by the ingestion of a composition containing β-casein A². A dietary supplement formed by the addition of β-casein to a food or drink for human consumption where the β-casein is comprised of at least 95% β-casein A², preferably solely β-casein A².

In the method, reaction between polyclonal antibody of anti apolipoprotein M and apolipoprotein M of sample to be tested forms compound, which causes change of cloudiness. The change is expressed by intensity of light transmission or intensity of light scattering. Content of apolipoprotein M of sample to be tested is looked out from curve between concentrations of standard apolipoprotein M and relevant intensity of light transmission or intensity of light. Titer of polyclonal antibody is at least 1:128 containing multi antigenic determinant. Sample to be tested is human blood plasma or serum in empty stomach diluted. Polyclonal antibody of anti apolipoprotein M is mixed with diluted sample. Features of thee method are: convenience, good repeatability, and high adaptability.

Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps. Thus, the iPSC hepatocytes in the bioartificial liver device maintained the secretory function and exhibited cell maturation.

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.

Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.

The invention discloses a VHH chain of a nano antibody of apolipoprotein B, which comprises a framework region (FR) and a complementary determining region (CDR). The invention discloses an amino acid sequence of the FR selected from the lower group and an amino acid sequence of the CDR. The invention also discloses an apolipoprotein B nano antibody and a DNA molecule for coding the VHH chain of the nano antibody of apolipoprotein B or the apolipoprotein B nano antibody, and discloses a host cell capable of expressing the nano antibody of apolipoprotein B. Moreover, the invention discloses an application of the apolipoprotein B nano antibody for detecting the apolipoprotein B. Through the nano antibody gene sequence and host cell disclosed by the invention, the nano antibody can be efficiently expressed in Escherichia coli and is used for developing an apolipoprotein B detection reagent.

The invention provides a rapid purification method of apolipoprotein B, comprising the following steps of: A) taking human plasma and adding a buffering solution to be diluted and uniformly mixed; B) placing an obtained diluted plasma sample into a first water bath with the temperature of 65-75 DEG C to be heated; centrifuging and taking liquid supernatant; C) adding a surfactant with the volume percentage of 0.5-3% into the liquid supernatant and uniformly mixing to obtain processed liquid supernatant; D) placing the treated liquid supernatant into a second water bath with the temperature of50-60 DEG C to be heated; centrifuging, removing the liquid supernatant and collecting sediments; and E) washing the sediments by using a Tris-HCl buffering solution with the concentration of 0.01-0.1 mol/L for two times, and filtering to obtain purified apolipoprotein B. The rapid purification method of the apolipoprotein B, disclosed by the invention, has the advantages of being simple in operation steps, simple in needed equipment and high in purity of a purified product, and effectively reduces the purification cost.

Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders, including cardiovascular disease, diabetes and hypertension in mammals including domestic pets and humans. Apolipoprotein C-II or its active fractions can be used as a diet supplement in the form of fortification to a natural product such as milk, cereal, beverage; as a nutritional supplement; or as a therapeutic agent in conventional forms of administration.

Disclosed is an immunogenic hybrid polypeptide for the prevention and treatment of obesity, in which a mimetic peptide of a B cell epitope of apolipoprotein B-IOO; a rabies virus helper T cell epitope or hepatitis B virus surface antigen helper T cell epitope and a C-terminal peptide fragment of mouse apolipoprotein Cu or a mimetic peptide of a B cell epitope of apolipoprotein B-100 are fused to each other in that order in the direction from the N terminus to the C terminus thereof. Also, a vaccine composition for the prevention and treatment of obesity, comprising the immunogenic hybrid polypeptide is disclosed, along with a polynucleotide encoding the immunogenic hybrid polypeptide, a recombinant expression vector carrying the polynucleotide, a host cell anchoring the recombinant expression vector, and a method for producing the immunogenic hybrid polypeptide by culturing the host cell transformed with the recombinant expression vector.

The invention belongs to the technical field of biology, and particularly relates to SgRNA targeting an APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like protein 3 protein G) gene and a method for knocking out the macaca fascicularis APOBEC3G gene. In allusion to mRNA of the macaca fascicularis APOBEC3G gene, a target sequence is established and the corresponding sgRNA is synthesized, and then a knockout vector is constructed for co-transfecting macaca fascicularis embryo fibroblasts to obtain APOBEC3G gene-knocked macaca fascicularis embryo fibroblasts, or the sgRNA and Cas9 mRNA are mixed and injected into a macaca fascicularis embryo to obtain the APOBEC3G gene-knocked macaca fascicularis embryo. Detection and identification of a knockout effect show that the gene knockout of the APOBEC3G gene on macaca fascicularis cells and the macaca fascicularis embryo can be effectively achieved, so that a solid foundation is laid for establishment of an AIDS (acquired immunodeficiency syndrome) animal model.

Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1 can be taken up by cells in the form of a delivery vehicle, such as a liposome or niosome, or directly as a chimeric protein which includes a first polypeptide that includes a protein transduction domain and a second polypeptide that includes APOBEC-1 or a fragment thereof which can edit mRNA encoding apolipoprotein B.

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

The invention relates to a polypeptide (RLT polypeptide)-mediated docetaxel tumor targeting submicroemulsion combined with a low density lipoprotein binding domain in an apolipoprotein B, and a preparation method thereof, which belong to the medical technology field. The submicroemulsion is the tumor targeting submicroemulsion prepared from oil for injection, emulsifying agents, auxiliary emulsifying agents, antioxygen, isoosmotic adjusting agents, bi-stearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, RLT polypeptide and docetaxel. The weight volume concentration range of the docetaxel is 0.5-20mg/mL. The tumor targeting submicroemulsion has uniform grain size, and the average grain size is 182nm. The docetaxel submicroemulsion is modified by tumor targeting cells, so that the tumor targeting efficiency is obviously improved, the distribution of medicine in the tumor cells is increased, and other normal medicine dose is reduced. Therefore, due to the RLT polypeptide-mediated docetaxel tumor targeting submicroemulsion, the therapeutic effect of the medicine can be improved, and the toxic and side effects are reduced.

Provided are methods for inhibiting cancer cell growth comprising contacting the cancer cell with an agent which inhibits the expression of the gene, or the activity of, apolipoprotein B editing catalytic 3G (APOBEC3G). Also provided are methods for identifying agents which can induce or inhibit C>U deamination in RNA driven by apolipoprotein B editing catalytic proteins. The method comprises contacting APOBEC3G with a suitable RNA substrate and determining the extent of C>U deamination under conditions which induce APOBEC driven C>U deamination.